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Abstract 
 
Objective: To investigate the association between urinary biomarker Coll2-1NO2 (uColl2-
1NO2) and incident knee OA after 2.5 years follow-up in middle-aged overweight and obese 
women at high risk for knee osteoarthritis (OA). 
Design: Data were used from PROOF, a randomized controlled trial with 2.5 years follow-up 
evaluating the preventive effects of a diet and exercise program and oral glucosamine 
sulphate (double blind and placebo controlled), on development of incident knee OA in 
women with body mass index ≥ 27 kg/m2 without signs of knee OA at baseline. Baseline and 
2.5 years uColl2-1NO2 concentrations were assessed with ELISA. Primary outcome measure 
was incidence of knee OA in one or both knees, defined as incidence of either Kellgren & 
Lawrence grade ≥ 2, joint space narrowing of ≥ 1.0 mm or knee OA according to the 
combined clinical and radiographic ACR-criteria. We used binary logistic regression for the 
association analyses. 
Results: 254 women were available for analyses. At 2.5 years follow-up, incident knee OA 
was present in 72 of 254 women (28.3%). An inversed association was found between 
baseline uColl2-1NO2 and incident knee OA at 2.5 years (OR 0.74, 95% CI 0.55 – 0.99). The 
concentration at 2.5 years and the change in concentration over 2.5 years did not show 
significant associations with the outcome.  
Conclusions: In overweight and obese middle-aged women, not higher but lower baseline 
uColl2-1NO2 concentration was significantly associated with an increased risk for incident 
knee OA. This interesting but counterintuitive outcome makes further validation of this 
biomarker warranted. 
 
Keywords   knee, osteoarthritis, biomarker, Coll2-1NO2 
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Introduction 
 
Up to now there is no curative treatment for knee osteoarthritis (OA), only symptomatic 
treatment for pain and loss of function exists1. In this context it may be sensible to increase 
the focus on prevention of the initial development of knee OA2. In order to progress in this 
area we need to detect knee OA in an earlier, preclinical and preradiographic phase.  
Currently, no sufficient tools for this aim exist. Plain knee radiography for measuring 
joint space width has a relatively large precision error and low sensitivity3. Magnetic 
resonance imaging (MRI) is more sensitive in detecting features of knee OA4, but is not 
extensively applicable due to costs, long scan time and limited availability1. Given the 
limitations of imaging biomarkers for pre-clinical or pre-radiographic knee OA, biochemical 
markers are investigated as alternatives5. One of these, the Coll2-1NO2 peptide, represents 
the combination of collagen type II degradation products (Coll2-1) and reactive nitrogen and 
oxygen species (RNOS), NO and O2-, and can be measured systemically in urine or serum6. 
Elevated production of RNOS has been observed in chronic inflammatory conditions, 
including established OA, but the effect of the preclinical and preradiographic phase of OA is 
still unknown7. As a low grade chronic inflammation has been suggested to be involved in the 
development of OA , before visible cartilage degeneration has occurred8, we might 
hypothesize that elevated RNOS levels and thus elevated Coll2-1NO2 concentrations could 
be measured in the pre-OA phase as well.  
The aim of this study is therefore to explore the potency of Coll2-1NO2 in detecting 
disease activity in preclinical and preradiographic knee OA, as earlier diagnosis of disease 
activity enables development of preventive therapies. We explored whether the baseline 
uColl2-1NO2 concentration in subjects at risk for developing knee OA was associated with 
incident knee OA 2.5 years later. Additionally, we explored whether the concentration at 2.5 
years was cross-sectionally associated and whether the change in concentration over 2.5 
years was associated with incident knee OA.  
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Method 
 
Study design, setting, and population 
We used data from the PROOF study (Prevention of knee Osteoarthritis in Overweight 
Females, ISRCTN 42823086)9. The PROOF study is a randomized controlled trial, with a 2x2 
factorial design and 2.5 years follow-up, which evaluates the preventive effects of a diet and 
exercise program (DEP) and of oral glucosamine sulphate, double blind and placebo 
controlled (GSvP), on the development of knee OA in overweight and obese middle-aged 
women. Inclusion criteria were age 50-60 years and BMI ≥ 27 kg/m2 , as those are proven 
risk factors for knee OA10, 11. All participants were recruited by their General Practitioner (GP) 
and had to be free of knee OA according to the clinical and radiographic criteria of the 
American College of Rheumatology (ACR)12. The participants had to master the Dutch 
language and had to be free of major co-morbidities, free of inflammatory rheumatic 
diseases, not under treatment of a physical therapist or GP for knee complaints, not using 
walking aids and not using oral glucosamine for the last 6 months. We treated data from 
PROOF as a pre-clinical OA cohort by adjusting analyses for the randomization groups. The 
Medical Ethics committee of Erasmus MC University Medical Center Rotterdam approved 
the PROOF study and all the participants gave written informed consent.    
 
Radiography 
Posterior-anterior radiographs of both knees were taken at baseline and at 2.5 years, using 
the semi-flexed MTP view13. A trained researcher blinded for clinical outcomes (MR) scored 
all radiographs, baseline and follow-up at once with known sequence using the Kellgren & 
Lawrence (K&L) criteria14. A random subset of 20% of the radiographs was independently 
scored by a second researcher (JR) blinded for clinical outcomes. The Cohen’s kappa 
6 
 
measure of agreement was moderate with a value of 0.6. Minimal joint space width was 
measured digitally in each tibiofemoral compartment, according to the method of Lequesne15, 
using the average independent score of two researchers (JR and BdV), blinded for the 
clinical outcomes. Scores with a difference ≥ 2.0 mm between the researchers were re-
evaluated in a consensus meeting. The inter-observer agreement for medial and lateral joint 
space narrowing was substantial with kappa values of 0.67 and 0.76, respectively. Medial 
anatomical knee alignment angle was assessed on knee radiographs as described 
previously16. Normal alignment was defined as angles between 182° and 184°, valgus and 
varus alignment were defined as angles > 184° and <182° respectively17. The test for 
reproducibility showed good agreement for alignment with kappa of 0.716. 
 
Assessment of Coll2-1NO2 
uColl2-1NO2 was determined at baseline and at 2.5 years in non-fasted, second morning 
void urine samples. The assessment in urine was based upon the qualification of the 
biomarker according to the BIPED classification: Coll2-1NO2 in urine is qualified as biomarker 
of prognosis18.  A detailed description of the identification of Coll2-1NO2 can be found in 
previous publications18, 19. In short, uColl2-1NO2 concentration was assessed by enzyme-
linked immunosorbent assay (ELISA) based on the method described by Rosenquist et al20 
using a polyclonal antibody against antigenic determinants of uColl2-1NO2 according to the 
instructions of the manufacturer (Artialis s.a, Liège, Belgium). 150 µl of urine was needed for 
each sample. After thawing, total assay time was within a maximum of 3 hours. The precision 
of the immunoassay of Coll2-1NO2 in urine was previously established by Deberg et al18 and 
demonstrated an intra-assay coefficient of variation (CV) of 8.3% and an inter-assay CV of 
13.6%.  In our study, uColl2-1NO2 was measured in triplicate and two additional urine 
samples were added on each plate as control. The inter-assay CVs for these two controls 
were respectively 9.6 and 11%. 
uColl2-1NO2 concentration was adjusted for urinary creatinine concentrations by expressing 
the results as nmol/mmol (nM/mM) creatinine. The creatinine was measured by the method 
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of Jaffé21 with the MicroVue Creatinine Assay Kit (Quidel, San Diego USA) on a MEGA 
autoanalyzer (Merck, Germany). 
 
Questionnaires, physical examination and blood samples 
At baseline all subjects filled in a questionnaire to record demographic (age, BMI, 
postmenopausal status, ethnicity) and clinical characteristics including questions on injury, 
physical activity (measured with the Short QUestionnaire to ASsess Health-enhancing 
physical activity (SQUASH)22), knee complaints (“did you experience knee pain in the past 12 
months?”) and ‘self-reported’ OA in other joints. Body weight, body height, blood pressure, 
abdominal circumference, skin folds and Heberden’s nodes on both hands were assessed at 
the research center. Non-fasted HbA1c concentration (mmol/mol) and total cholesterol 
concentration (mmol/L) were determined from blood samples taken at baseline.  
 
Outcome  
The primary outcome measure of this study was incidence of knee OA in one or both knees 
at 2.5 years. Incidence of knee OA was defined as either Kellgren & Lawrence (K&L) grade ≥ 
2, joint space narrowing (JSN) of ≥ 1.0mm23 or knee OA according to the combined clinical 
and radiographic ACR criteria (ACR knee OA). Secondary outcome measures were the 
separate clinical and radiographic definitions of the primary outcome. 
 
Statistical analysis 
For the present study, participants with available baseline and 2.5 years uColl2-1NO2 
concentrations and with a complete follow-up were included for analysis. Baseline 
characteristics were described as percentages for categorical/dichotomous data and as 
means ± standard deviation (SD) or medians (interquartile range, IQR) for continuous data. 
For exploratory analyses, we conducted paired and independent-samples Student’s t-tests 
with untransformed uColl2-1NO2  data; The paired t-test to evaluate the difference between 
mean uColl2-1NO2 at baseline and 2.5 years within the incident and non-incident knee OA 
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women; The independent-samples t-tests to compare baseline-, 2.5 years- and change over 
2.5 years- concentrations between the women with and without incident knee OA.  
For the regression analyses of uColl2-1NO2  with primary and secondary outcomes, uColl2-
1NO2 was logarithmically transformed to obtain normally distributed residuals. First, possible 
confounding variables and prognostic factors in the association of uColl2-1NO2  with the 
primary and secondary outcomes were determined by univariable linear regression analyses. 
The selection of the different demographic, metabolic, functional and radiographic variables 
was based on their possible relation with uColl2-1NO2 and knee OA10, 19, 24. Variables with a 
univariable p-value < 0.2 and with an r-value < 0.7 (cut-off point for multicollinearity) were 
adopted in a multivariable regression analysis (using the Enter method) to analyse significant 
associations with uColl2-1NO2.  
Subsequently, we analysed the association of uColl2-1NO2 with the primary and secondary 
outcome measures. First, we determined the association of baseline uColl2-1NO2 through 
binary logistic regression, using 3 different models. The first model was unadjusted, the 
second model was adjusted for age and BMI, as these are established risk factors for knee 
OA. The fully adjusted model 3 was adjusted for age, BMI, randomization groups (DEP, 
GSvP and their multiplicative interaction), possible confounders and prognostic factors from 
the multivariable analysis and for K&L grade at baseline (0 versus 1), as this has already 
been shown to be a prognostic factor for incident knee OA in the PROOF study25. Next, we 
analysed the cross-sectional associations of uColl2-1NO2 with prevalent knee OA and 
secondary outcomes at 2.5 years to evaluate the diagnostic value of uColl2-1NO2 . Finally, 
we analysed the association of the change in uColl2-1NO2 concentration over 2.5 years, 
corrected for baseline concentration, with the primary and secondary outcomes. All analyses 
were performed with the three models.  
To facilitate interpretation of the regression associations, uColl2-1NO2 was standardized into 
z-scores. Results for the regression analyses were presented as odds ratios per standard 
deviation (SD) increase in log uColl2-1NO2 and their corresponding 95% confidence 
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intervals. Statistical analyses were performed with SPSS 20.0 (Chicago, IL). A p-value < 0.05 
was defined as statistically significant.  
 
Results 
 
Characteristics of the study population 
254 of 407 women with mean age of 55.8 years ± 3.19 and mean BMI of 31.0 kg/m2 ± 3.97 
were available for current analyses. The reasons for missing data were as follows: 1) 
unwilling to continue participation (28/407), 2) unattainable during follow-up (12/407), 3) no 
urine to the lab (8/407) 4) sample below the limit of detection of the test (61/407), 5) excluded 
based on K&L >=2 at baseline (42/407) and 6) deceased during follow-up (2/407). Analysis 
of the baseline differences between missing and non-missing subjects showed a statistically 
significant higher fat percentage (44.4% vs 43.0%), lower cholesterol concentration 
(5.9mmol/L vs 6.1mmol/L) and a higher percentage of varus alignment (55.7% vs 44.8%) in 
those missing. These differences did not seem to be relevant, as no correlation of these 
variables with Coll2-1NO2  was found. Distribution, means and/or medians of baseline 
characteristics are displayed in table 1. 
Incident knee OA according to the primary outcome was found in 72/254 women (28.3%). 
Medial joint space narrowing (JSN) was found in 27/254 (10.6%), lateral JSN in 26/254 
(10.2%), ACR defined knee OA in 20/254 (7,9%) and K&L grade ≥ 2 in 23/254 women 
(9.1%).  
 
Exploratory associations between uColl2-1NO2 and incident knee OA 
Mean uColl2-1NO2 concentration for the total study group was 0.033nM/mM creatinine ± 
0.017 at baseline and 0.034nM/mM ± 0.017 at 2.5 years. The mean creatinine value of all 
samples was 7.69mM/L ± 4.36. Mean baseline uColl2-1NO2 concentration was significantly 
lower in the women with incident knee OA as primary outcome after 2.5 years compared to 
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the women without incident knee OA (0.029nM/mM ± 0.013 versus 0.034nM/mM ± 0.017, p = 
0.03). The concentration at 2.5 years showed no significant difference between the women  
with and without incident knee OA (0.034nM/mM ± 0.018 versus 0.034nM/mM ± 0.017, p = 
0.76). Although the change from baseline over 2.5 years within both groups was not 
significant, the change between both groups was. The mean increase in the women with 
incident knee OA was 0.005nM/mM ± 0.021 versus a mean decrease of  0.001nM/mM ± 
0.020 in the women without incident knee OA (p = 0.04), see figure 1.  
   
Baseline associations between uColl2-1NO2 and incident knee OA  
The variables ethnicity (Caucasian), weight, Heberden’s nodes, SQUASH score and ‘self-
reported’ OA in other joints were positively associated with uColl2-1NO2. Age and years 
since menopause were negatively associated with uColl2-1NO2. The variables BMI, waist 
circumference, fat percentage, total cholesterol, HbA1c, K&L grade 0 vs 1, knee alignment, 
mild knee symptoms and history of knee injury were not univariable associated with uColl2-
1NO2. In the multivariable regression analyses, none of the variables were significantly 
associated with uColl2-1NO2. 
The associations of baseline uColl2-1NO2 with primary and secondary outcomes are 
displayed in table 2, showing a significant inversed association between baseline uColl2-
1NO2 and incident knee OA at 2.5 years, both in adjusted model 2 and 3 (OR 0.74, 95% CI 
0.55-0.99 in model 3). No significant associations were found for the secondary outcomes.  
 
Associations of uColl2-1NO2 at 2.5 years and prevalent knee OA 
The uColl2-1NO2 concentration at 2.5 years did not show a significant cross-sectional 
association with prevalent knee OA (OR 1.03, 95% CI 0.77 – 1.37 in model 3) or with the 
separate outcome definitions, in any of the models (medial JSN: OR 0.93, 95% CI 0.63 – 
1.38, lateral JSN: OR 0.88, 95% CI 0.57 – 1.34 , ACR knee OA: OR 1.39, 95% CI 0.82 – 
2.37, and K&L ≥ 2: OR 0.92, 95% CI 0.57 – 1.47, all in model 3). 
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Change of uColl2-1NO2 and incident knee OA 
No significant association was found between the change in concentration over 2.5 years 
and incident knee OA (OR 1.10, 95% CI 0.81 – 1.48 in model 3), nor for the association with 
the separate outcome definitions, in any of the models (medial JSN: OR 0.94, 95% CI 0.62 – 
1.41, lateral JSN: OR 0.88, 95% CI 0.57 – 1.36, ACR knee OA: OR 1.55, 95% CI 0.88 – 
2.72, and K&L ≥ 2: OR 0.97, 95% CI 0.60 – 1.57, all in model 3).  
 
Discussion 
 
This is the first study that assessed the uColl2-1NO2 biomarker in a high-risk pre-OA cohort 
of middle-aged overweight and obese women. We found that a lower baseline uColl2-1NO2 
concentration was significantly associated with an increased risk of incident knee OA after 
2.5 years. The cross-sectional association between uColl2-1NO2 at 2.5 years and prevalent 
knee OA and the association between the change of uColl2-1NO2 and incident knee OA were 
not statistically significant.  
 
Context  
Serum Coll2-1NO2 was found to be significantly elevated in knee OA patients, compared to 
age-matched controls19. In another knee study, the one year uColl2-1NO2 change from 
baseline, was shown to be predictive for radiographic medial joint space narrowing over 3 
years18. Our study, unlike the others, was performed with patients at risk for knee OA instead 
of established knee OA.  
Against our expectations, a lower baseline uColl2-1NO2  concentration was found in 
the women who developed incident knee OA, compared to those who did not. In vitro 
studies26-28 indicate that in the development of OA, besides catabolic inflammatory 
processes, compensatory anti-inflammatory mechanisms occur in an attempt by 
12 
 
chondrocytes to restore cartilage homeostasis27. In vitro studies show that anti-inflammatory 
cytokine IL-10 can inhibit NO expression28 and can antagonize chondrocyte apoptosis26. 
These studies might give some support for our, somewhat counterintuitive finding of lower 
baseline uColl2-1NO2 formation. However, we can only speculate on the role of anti-
inflammatory mechanisms, as this had not been studied comprehensively so far in the 
context of OA29. Moreover, some studies suggest that the anti-inflammatory response may 
never control the inflammatory response in OA completely30. We do not know how this 
balance is acting in the preclinical and preradiographic phase as studied in the present study. 
Besides, we might also hypothesize that subjects who develop OA have initially lower 
amounts of cartilage, which reduce the overall formation of uColl2-1NO2.  
We did perform our analyses on person level instead of knee level for different 
reasons. First, we had the aim to analyse the associations for women and not for knees. The 
biomarker was furthermore measured systemically and not locally. Moreover, a total of 72 
women developed knee OA after 2.5 years follow-up, but only 14 of them had bilateral knee 
OA. As a result, this would not provide enough power to distinguish between uni- and 
bilateral knee OA. In ordinal regression analyses (data not shown) we found stronger, but not 
significant, associations for bilateral compared to unilateral knee OA.  
In our exploratory analyses, we found a significant difference in change of uColl2-
1NO2 concentration over 2.5 years between incident and non-incident knee OA. Previously, 
Deberg et al suggested that uColl2-1NO2 levels do not increase in preclinical and 
preradiographic OA phase, but later in OA development18. This is supported by the significant 
increase of uColl2-1NO2 in women with incident knee OA compared to the women without 
knee OA development. This increase of uColl2-1NO2 over time might be caused by the 
eventual failure of the above mentioned compensatory anti-inflammatory mechanisms during 
further development of knee OA. However, the significance is found only in our exploratory 
non-logarithmically transformed analyses.  
In the 2.5 years cross-sectional data and in the change of uColl2-1NO2  concentration 
over 2.5 years, the positive association with ACR knee OA was most pronounced, albeit not 
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statistically significant. The absence of significance might be due to the small number of 
women who developed ACR knee OA (20/254, 7.9%) or the relatively short follow-up period 
of 2.5 years. The relation between (chronic) inflammation and knee pain31, 32 and between 
(chronic) inflammation and osteophytes33 as described in literature, seems to be reflected by 
this finding of a positive trend for the association between uColl2-1NO2 (inflammatory marker) 
and ACR knee OA (pain and osteophytes).  
 
Strengths and limitations 
The major strength of this study is its focus on preclinical and preradiographic  knee OA. 
Especially in high risk subjects there is a need for tools that could help detecting disease 
activity in this phase of knee OA. The assessment of the potency of the uColl2-1NO2 
biomarker in this study is contributing to fulfil this need.   
We are aware of the relatively high number of analyses performed, resulting in an 
increased risk of a type I error. Nevertheless, given the exploratory nature of this study, these 
results should be seen as the first step in the validation of the uColl2-1NO2 biomarker in high-
risk pre-OA women.  
One of the limitations of this study is that we could not undoubtedly exclude the 
presence of OA in other joints than the knee, which might have influenced the level of 
systemic uColl2-1NO2. However, we have taken the presence of Heberden’s nodes and the 
self-reported OA in other joints into account in our analyses. Choosing for self-reported OA is 
used in more studies34, 35. Moreover, the participants in the present study were asked to 
identify the location of their OA from a list of five (hip, ankle, hand, back/neck, other), which is 
known to improve the accuracy of self-reporting36. In this way we intended to correct as 
precisely as possible, making the results applicable to the knee joints.  
 
Conclusions and implications 
In this study of overweight and obese middle-aged women at risk for developing knee OA, 
lower baseline uColl2-1NO2 levels were significantly associated with increased risk of overall 
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incidence of knee OA 2.5 years later. These results might be caused by compensatory 
mechanisms in the preclinical and preradiographic phase of the pathophysiologic process, 
lower NO production or an overall lower cartilage volume in people developing knee OA.  
In the preclinical and preradiographic phase, distinguishing subjects who are at risk to 
develop definite knee OA from those who are not, has a high priority. It seems important to 
further validate the Coll2-1NO2 biomarker and to increase our understanding of this very 
early phase of knee OA to enable development of preventive therapies for those subjects 
prone to develop knee OA.    
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Table 1. Mean (± SD) or median (IQR) of baseline variables. 
SD = standard deviation. IQR = interquartile range. * Higher scores represent higher physical activity. ** Higher scores represent more 
pain/stiffness/worse function. *** JSW: joint space width
. 
N-subjects 
 
254 
General   
Age (yr) 55.8 ± 3.19 
Ethnicity  
     Western 
     Other 
95.7% 
3.1% 
Postmenopausal status 69.7% 
Years postmenopausal 7.6 ± 5.3 
 
Metabolic  
 
BMI (kg/m2) 31.9 ± 3.97 
Weight (kg) 87.3 ± 12.7
Physical activity score (SQUASH)* 
 
7058.3 ± 3672.4 
 
  
Joint specific  
Heberden's nodes 27.2% 
WOMAC (0 – 100)**  
     Pain 6.2 ± 10.13 
     Function 6.2 ± 10.13 
     Stiffness 11.4 ± 17.0 
 K&L   
    grade 0 bilateral 45.3% 
    grade 1 unilateral 22.4% 
    grade 1 bilateral   32.3% 
Minimal JSW***  
     medial (mm) 4.9 ± 0.7 
     lateral (mm) 6.1 ± 0.9 
Varus alignment  
     Unilateral 17.7% 
     Bilateral  26.8% 
Mild symptoms  
     Unilateral 25.6% 
     Bilateral 17.3% 
History of knee injury  
     Unilateral 17.7% 
     Bilateral 2.8% 
 
Biomarker 
Mean uColl2-1NO2/creatinine (nM/mM) 
Median uColl2-1NO2/creatinine (nM/mM)  
0.0330 ± 0.0165 
0.0313 (IQR 0.0220 – 0.0406) 
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Figures 
 
Figure 1: uColl2-1NO2 (nM/mM) levels at baseline and 2.5 years follow-up for women without 
and with incident knee OA at 2.5 years, not adjusted for BMI, age, K&L grade (0 vs 1) and 
randomization groups. P-values obtained from paired t-tests, to evaluate the difference 
between mean uColl2-1NO2 at baseline and 2.5 years within the incident and non-incident 
knee OA women. P-value* is obtained from unpaired t-test, to compare the change over 2.5 
years in the women with and without incident knee OA. P-value** is obtained from unpaired t-
test, to compare the baseline difference in women with and without incident knee OA.  
BL = Baseline, FU = Follow-up 
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Table 2. Multivariable adjusted association between  uColl2-1NO2 and adjusted variables age, BMI and K&L grade (0 vs 1) at 
baseline and overall incident knee OA and separate incidence definitions, at 2.5 years.  
Bold indicates p-value < 0.05 
CI = confidence interval. OA = osteoarthritis 
† Incidence of knee OA at 2.5 years: either Kellgren & Lawrence grade ≥ 2, joint space narrowing (JSN) of ≥ 1.0mm or knee OA according to the combined clinical and radiographic ACR criteria 
‡ secondary outcomes: separate definitions of incidence of knee OA 
* model 1: unadjusted 
** model 2: adjusted for age and body mass index 
*** model 3: adjusted for age, body mass index, randomisation groups, interaction between randomisation groups and K&L grade (0 vs 1) at baseline
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 
 
 
    uColl2-1NO2 Age BMI K&L 0 vs 1 
 Cases (%)  OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Incident knee OA† 
 
72/254 
(28.3) 
Model 1* 
 
0.77 0.58 – 1.02 - - - 
  Model 2** 
 
0.74 0.56 – 0.99 1.03 0.94 – 1.22 1.10 1.03 – 1.18 - 
  Model 3***
 
0.74 0.55 – 0.99 1.02 0.94 – 1.12 1.09 1.01 – 1.17 1.77 0.98 – 3.20 
Medial JSN‡ 
 
27/254 (10.6)  Model 1* 
 
0.99 0.65 – 1.49 -  - - 
  Model 2** 
 
0.83 0.63 - 1.46 
 
0.99 0.87 – 1.13 1.08 0.98 – 1.18 - 
  Model 3*** 
 
1.00 0.61 - 1.49 1.00 0.88 – 1.13 1.06 0.96 – 1.16 1.37 0.58 – 3.23 
Lateral JSN‡ 
 
26/254  
(10.2) 
Model 1* 
 
0.95 0.63 – 1.44 - - - 
  Model 2** 
 
0.94 0.62 – 1.43 1.02 0.89 – 1.16 1.05 0.95 – 1.16 - 
  Model 3*** 
 
0.95 0.63 – 1.43 1.02 0.89 – 1.17 1.10 0.99 – 1.22 0.38 0.16 – 0.93 
ACR criteria‡ 
 
20/254 
(7.9) 
Model 1* 
 
0.77 0.51 – 1.18 - - - 
  Model 2** 
 
0.72 0.47 – 1.12 0.96 0.83 – 1.12 1.11 1.00 – 1.23 - 
  Model 3*** 
 
0.70 0.43  - 1.12 0.96 0.83 – 1.12 1.07 0.97 – 1.19 7.87 1.74 – 35.55
KL ≥ 2‡ 
 
23/254  
(9.1) 
Model 1* 
 
0.83 0.55 – 1.25 - - - 
  Model 2** 
 
0.78 0.50 – 1.20 1.08 0.93 – 1.25 1.18 1.08 – 1.30 - 
  Model 3*** 0.74 0.47 - 1.18 1.07 0.93 – 1.24 1.15 1.04 – 1.26 3.44 1.09 – 10.85
